Article Topics
Clinical Trials 2022 Will Remain a Witness to
The year 2022 is yet to remain witness to some outstanding clinical trials. These clinical trials have the potential to change the history of medicine, and the entire world is eagerly looking forward to the verdicts. Even though there have been a lot of disruptions owing to none other than COVID-19 for the last two years, the world of medicine has been successful in moving ahead and also coming out successful in many trials in the year 2021. Similarly, 2022 also has some exciting and revolutionary trials in progress. If you want to know more on decentralized clinical trials, this is the correct blog for you. Read on to learn about some of the most important clinical trials upcoming this year.
Sacituzumab Govitecan-hziy for PD-L1 Positive
The main focus of this study is to find a comparison of the PFS, i.e., progression-free survival between pembrolizumab and the sacituzumab govitecan-hziy (SG) versus the treatment of TPC, i.e., physician’s choice and pembrolizumab. This study will be done on participants with locally advanced metastatic or inoperable triple-negative breast cancer, who have not been previously treated, and whose tumors express a programmed cell death ligand 1. The eligible conditions should be breast cancer and PD-L1 Positive. The measurement will take place over the period of first dose days up to 53 months plus additional 30 days. As far as trial safety is concerned, this study is 85% better than similar clinical trials.
Patritumab Deruxtecan for EGFR Exon 19 Deletion
The main focus of this study is to bring a comparison between the efficiency of platinum-based chemotherapy versus patritumab deruxtecan. This is measured by the OS (the key secondary endpoint of overall survival) and the progression-free survival within participants who have metastatic or locally advanced NSCLC. With an exon 19 deletion or L858R (with an EGFR-activating mutation) after the failure of a third-generation EGFR TKI therapy (example, lazertinib, osimertinib, alflutinib, and aumolertinib). The eligible conditions are EGFR L858R, Nonsquamous Non-small Cell lung cancer, and EGFR Exon 19 Deletion. The period for measurement over the course of the entire baseline is up to 49 months. This study is about 85% better than other similar studies.
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
The primary objective of this study is to evaluate whether CBD brings any improvement to CIPN when compared to a placebo. It also focuses on the side effects of topical cannabidiol cream when compared to a placebo. Among its other objectives are the assessment of adverse event profiles using the symptom questionnaires and CTCAE version (v)5.0. This study also aims to measure Neuropathy as it is measured by the Quality of Life Questionnaire, the EORTC QLQ CIPN20 autonomic scale, the European Organization for Research and Treatment of Cancer, and the total Common Terminology Criteria for Adverse Events neuropathy scale. The study started in June 2022 and is estimated to be completed by April 2024. There are over forty participants who are taking part in this study.
Reducing Pain and Opioid Use with CBD
The main objective of this study is to understand the impacts of hemp-derived cannabidiol, both with and without a small amount of THC. The study proposes a phase II random clinical trial to properly examine the safety, clinical impacts, and tolerability of Full Spectrum cannabidiol (fsCBD, which contains less than 0.2% THC) versus Broad Spectrum cannabidiol versus a placebo that is matching in a population of opioid users. This study is a placebo-controlled, double-blind parallel-group study that helps to assess the efficiency and also the tolerability of bsCBD and fsCBD, compared to a placebo-control, in order to reduce anxiety, pain, opioid use, improve sleep, and other cognitive functions. There are around 150 participants chosen for this study.
Cannabidiol and Focus Study
This is a placebo-controlled, double-blind 4-arm clinical trial. Both the female and male participants will be made to undergo two pre-intervention study visits and three post-intervention study visits that will be separated by an 8-week intervention period. The participants will be 18-50 years old and should be engaged in at least 150 minutes of physical activity. This study will try to explore a potential cannabidiol mechanism of action, keeping in focus biomarkers of neural health, liver health, NKC number and function, inflammation, and kidney health.
Conclusion
The medical world is eagerly waiting for the conclusions of these exciting clinical studies. When these studies are successfully completed, they will surely take the medical world by storm. Technology is also changing clinical trial efficiency day by day. Let us all hope all these studies are successful in their trials and can help countless people in the future.
